explore -WSS

explore

author：focus 2025-09-27 13:10:26 - browse：6

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Health AI: on the border between health care and tech

entertainment

WSS

HIV vaccine remains elusive. Immunologists keep trying new ideas

Cytokinetics CEO stresses company can launch heart drug on its own

Addiction experts warn against a second 'war on drugs'

Military medical care influenced by rank and race, new study finds

It's time to retire 'poor historian' from clinicians' vocabularies

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

DIEP, the 'gold standard' of breast reconstruction, is under threat

Dozens dead from Maui wildfires: What we know about the victims

Psychedelics group wrestles with new pharma identity

Second House panel advances two

Alkermes shareholders re

Megan Rapinoe shares emotional post following US Women's World Cup exit

In Memoriam: Notable people who died in 2023

Military medical care influenced by rank and race, new study finds

23andMe had bad news about my health. I wish a person had delivered it

Aspartame and sugar

leisure time

Criminal prosecution for violating HIPAA: an emerging threat

HIV vaccine remains elusive. Immunologists keep trying new ideas

Solving academic medical centers' existential crisis

What to know about the judge who will handle the Trump case

Cytokinetics CEO stresses company can launch heart drug on its own

Idaho college killings prosecutors challenge defense's grand jury claims

entertainment

knowledge

knowledge

explore